HDAC9 and hepatocellular carcinoma: Hydroxamate HDAC inhibitors (e.g., resminostat, panobinostat, suberanilohydroxamic acid [SAHA]) could inhibit proliferation, induce apoptosis, and sensitize HCC cells to sorafenib.